This document discusses indications for cardiac implantable electronic devices (CIEDs) such as pacemakers, cardiac resynchronization therapy (CRT), and implantable cardioverter defibrillators (ICDs) according to guidelines. It covers classifications of bradyarrhythmias and indications for pacing in various conditions such as persistent bradycardia. Indications for CRT and ICDs are also outlined based on left ventricular ejection fraction, heart failure class, and other factors. Current health insurance reimbursement policies in Taiwan for these devices are also summarized.
ARVD is one of important coardiomyopathy in our clinical practice,early diagnosis, risk stratification and early diagnosis of CHF, management of VT will make big difference in patient life
In this ppt i am going to discuss various spotters, including ECG, X-ray, fluroscopy images and there answers. These spotter now days asked in various DM cardiology exam conducted all over India, so it will help you in your DM Cardiology exam preperationn.
ARVD is one of important coardiomyopathy in our clinical practice,early diagnosis, risk stratification and early diagnosis of CHF, management of VT will make big difference in patient life
In this ppt i am going to discuss various spotters, including ECG, X-ray, fluroscopy images and there answers. These spotter now days asked in various DM cardiology exam conducted all over India, so it will help you in your DM Cardiology exam preperationn.
Idiopathic VT refers to VT occurring in structurally normal hearts in the absence of myocardial scarring. Classification of monomorphic idiopathic VT includes outflow tract VT, fascicular VT, papillary muscle VT,annular VT, and miscellaneous (VT from the body of the RV and crux of
the heart). It is commonly seen in young patients and usually has a benign course. The 12-lead lectrocardiogram is critical in distinguishing the specific form and locations of idiopathic VT. Treatment options include medical therapy specific to the underlying mechanism of VT or catheter
ablation.
differentiating between supraventicular tachycardia and ventricular tachycardia in wide complex rhythm is always confusing and management is totally different. correct diagnosis will make dramatic difference in patient management.
Today, in addition to measurement of left ventricular ejection fraction, the simple 12-lead surface ECG remains the only evidence-based means of identifying patients who may obtain the substantial benefits of CRT
Idiopathic VT refers to VT occurring in structurally normal hearts in the absence of myocardial scarring. Classification of monomorphic idiopathic VT includes outflow tract VT, fascicular VT, papillary muscle VT,annular VT, and miscellaneous (VT from the body of the RV and crux of
the heart). It is commonly seen in young patients and usually has a benign course. The 12-lead lectrocardiogram is critical in distinguishing the specific form and locations of idiopathic VT. Treatment options include medical therapy specific to the underlying mechanism of VT or catheter
ablation.
differentiating between supraventicular tachycardia and ventricular tachycardia in wide complex rhythm is always confusing and management is totally different. correct diagnosis will make dramatic difference in patient management.
Today, in addition to measurement of left ventricular ejection fraction, the simple 12-lead surface ECG remains the only evidence-based means of identifying patients who may obtain the substantial benefits of CRT
XIII Reunión anual de la sección de Insuficiencia Cardiaca de la SEC
OVIEDO, 16-18 JUNIO 2016 HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS (HUCA)
http://secardiologia.es/insuficiencia/cientifico/ic-oviedo-2016
Conferencia invitada: Presentacion de la Guía de Insuficiencia Cardiaca 2016 de la SEC
VIERNES, 17 DE JUNIO 18:00-18:30 SALÓN DE ACTOS
Presenta: José Luis Lambert Rodríguez (Presidente de la Sección de Insuficiencia Cardiaca)
José Ramón González Juanatey, Santiago de Compostela
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
7. AV node dysfunction
First Degree AV block
Second Degree AV block
Mobitz Type 1 – Wenckebach
Mobitz Type 2
Third Degree AV block – Complete heart
block
Bifasicular/Trifasicular block
9. Second-Degree AV Block –
Mobitz I (Wenckebach block)
Progressive prolongation of the PR interval
until there is failure to conduct and a
ventricular beat is dropped
10. Second-Degree AV Block –
Mobitz II
Regularly dropped ventricular beats
2:1 block (2 P-waves for every 1 QRS complex)
12. Fascicular Block
Right bundle branch block
and left anterior hemiblock
Right bundle branch
block and left
posterior hemiblock
Complete left bundle
branch block
31. Indications for CRT in patients with
conventional pacemaker indications
and heart failure
32. 現行健保給付規定
應事先審查。
正常竇房節心律,LVEF<=35%且CLBBB(QRS寬度
>=0.12sec),且NYHA Functional Class III, IV
及經適當藥物治療仍不能改善之病患。
心房顫動之病患, LVEF<=35%且CLBBB(QRS寬度
>=0.12sec),且NYHA Functional Class III, IV
及經適當藥物治療仍不能改善之病患。
心室節律器依賴之病患,LVEF<=35%,NYHA
Functional Class III, IV及經適當藥物治療仍
不能改善者。
33.
34. Outline
Indications for pacing
Indications for cardiac resynchronization
therapy (CRT)
Indications for intra-cardiac defibrillator
(ICD) therapy
35. Class I Recommendations
Level of Evidence: A
With LVEF ≤ 35% due to prior MI who are at least 40
days post-MI and are in NYHA Functional Class II or
III
With LV dysfunction due to prior MI who are at least
40 days post-MI, have an LVEF ≤ 30%, and are in
NYHA Functional Class I
Who are survivors of cardiac arrest due to VF or
hemodynamically unstable sustained VT after
evaluation to define the cause of the event and to
exclude any completely reversible causes
36. Class I Recommendations
Level of Evidence: B
With nonischemic DCM who have an LVEF ≤ 35% and
who are in NYHA Functional Class II or III
With nonsustained VT due to prior MI, LVEF < 40%,
and inducible VF or sustained VT at
electrophysiological study
With structural heart disease and spontaneous
sustained VT, whether hemodynamically stable or
unstable
With syncope of undetermined origin with clinically
relevant, hemodynamically significant sustained VT or
VF induced at electrophysiological study
37. Class IIa Recommendations
Level of Evidence: B
To reduce SCD in patients with Long QT
Syndrome who are experiencing syncope
and/or VT while receiving beta blockers
38. Class IIa Recommendations
Level of Evidence: C
With unexplained syncope, significant LV dysfunction, and
nonischemic DCM
With sustained VT and normal or near-normal ventricular
function
With catecholaminergic polymorphic VT who have syncope
and/or documented sustained VT while receiving beta blockers
For the prevention of SCD in patients with ARVD/C who have
one or more risk factors for SCD
With HCM who have one or more major risk factors for SCD
With Brugada syndrome who have had syncope or documented
VT that has not resulted in cardiac arrest
With cardiac sarcoidosis, giant cell myocarditis, or Chagas
disease
For nonhospitalized patients awaiting transplantation